Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
AssigneeAmal Therapeutics SA
InventorsMadiha Derouazi, Elodie Belnoue
Life of this patent
Estimating the term…
Abstract
The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
Claims21
A method for eliciting or improving an immune response against one or more antigens selected from survivin, carcino-embryonic antigen (CEA) and achaete-scute homolog 2 (ASCL2) in a subject, wherein the immune response comprises presentation of multiple epitopes of the antigen(s) by MHC class I and/or MHC class II molecules, and wherein the method comprises administering a complex comprising:
- a) a cell penetrating peptide;
- b) at least three antigenic peptides comprising
- (i) a peptide having an amino acid sequence according to SEQ ID NO:
- 95,
- (ii) a peptide having an amino acid sequence according to SEQ ID NO:
- 96, and
- (iii) a peptide having an amino acid sequence according to SEQ ID NO:
- 97;
- and
- c) at least one TLR peptide agonist,
- wherein the components a)-c) are covalently linked to the subject.
Dependencies are inferred from the claim text.